Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Epidermal Growth Factor¿Í Transforming Growth Factor-¥á°¡ ÀÎü ÀÌÇà»óÇÇ¾Ï ¼¼Æ÷ÁÖÀÇ ¼ºÀå¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ °üÇÑ ¿¬±¸ A Study in the Effects of Epidermal Growth Factor and Transforming Growth Factors-¥á on the Growth of Human Transitional Cell Carcinoma Cell Lines

´ëÇѺñ´¢±â°úÇÐȸÁö 1998³â 39±Ç 1È£ p.45 ~ 50
¼Ò¼Ó »ó¼¼Á¤º¸
½Å±â¿ë/Ki Yong Shin ±è¼±Áø/ÃÖ¿øÈ£/ÃÖµµ¿¬/¹ÚÇØ¿µ/ÀÌÃá¿ë/°ø±¸/¿ì¿µ³²/±èµ¿ÇÑ/Sun Jin Kim/Weon Ho Choi/Do Yeon Choi/Hae Young Park/Tchun Yong Lee/Gu Kong/Young Nam Woo/Dong Han Kim

Abstract

¼­·Ð
ÇغÎÇÐÀû Ư¼º»ó ¿ä·Î »óÇÇ´Â Ç×»ó ¼Òº¯°ú Á¢ÃËÇÏ°í ÀÖ¾î ¿äÁß¿¡ Á¸ÀçÇÏ´Â ¿©·¯ °¡Áö ¹°
ÁúµéÀÌ ¿ä·Î ÀÌÇà»óÇǾÏÀÇ ¹ß»ý°ú ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ´Ù´Â °¡¼³°ú ¿©·¯ °¡Áö Áõ°Åµé
ÀÌ Á¦½ÃµÇ¾î ¿Ô´Ù. ¹æ±¤¿¡ ¹ß»ýÇÏ´Â ÀÌÇà»óÇǾÏÀº Àç¹ß°ú Ç¥À缺 Á¾¾çÀ¸·ÎºÎÅÍ Ä§À±¼º Á¾¾ç
À¸·ÎÀÇ ÁøÇà µîÀÌ ÀÓ»óÀûÀ¸·Î °¡Àå Áß¿äÇÑ Á¡À̸ç, ÀÌ¿¡ ´ëÇÏ¿© ¿ªÇÐÀû, º´¸®Á¶Á÷ÇÐÀû, ºÐÀÚ
»ý¹°ÇÐÀû ±Ô¸íÀÌ ½ÃµµµÇ¾î ¿ÔÀ¸³ª ¾ÆÁ÷µµ ¸¸Á·ÇÒ ¸¸ÇÑ °á°ú¸¦ ¾òÁö ¸øÇÏ°í ÀÖ´Ù. ¿äÁß¿¡ Á¸
ÀçÇÏ´Â ¹°Áúµé Áß ¿©·¯ °¡Áö ¼ºÀåÀÎÀÚµéÀº Á¤»ó ¼¼Æ÷ÀÇ ±â´ÉÀ» Á¶ÀýÇÒ »Ó ¾Æ´Ï¶ó, Á¾¾ç¼¼Æ÷
»ýÅÂÀÇ Áß¿äÇÑ Á¶ÀýÀڷμ­ ÀÛ¿ëÇÏ¿© Á¾¾çÀÇ ¹ß»ý, ¼ºÀå, ±¹¼ÒÀû ħÀ± ¹× ÀüÀÌ¿¡ ¿µÇâÀ» ¹ÌÄ¡
´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. ±× Áß¿¡¼­µµ epidermal growth factor(ÀÌÇÏ EGF)´Â 6,000 daltonÀÇ
ºÐÀÚ·®À» º¸ÀÌ´Â 53°³ÀÇ ¾Æ¹Ì³ë»êÀ¸·Î ÀÌ·ç¾îÁø °­·ÂÇÑ mitogen4À¸·Î ¼ö¿ëü
¿Í °áÇÕÇÏ¿© Á¤»ó¼¼Æ÷ÀÇ ¼ºÀå, ¼º¼÷ ¹× ¼Õ»óº¹±¸ »Ó¸¸ ¾Æ´Ï¶ó ¼¼Æ÷ÀÇ ¾ÏÈ­, ¾Ï¼¼Æ÷ÀÇ ¼ºÀå
ÃËÁø µî ¿©·¯ °¡Áö °úÁ¤¿¡ °ü¿©Çϴµ¥ ƯÈ÷ ¿ä Áß¿¡ »ý¹°ÇÐÀûÀ¸·Î È°¼ºÈ­µÈ ÇüÅ·Π³ôÀº ³ó
µµ·Î ¹è¼³µÇ¾î ÀÌÇà»óÇǾÏÀÇ Àç¹ßÀ̳ª ÁøÇà°úÀÇ ¿¬°ü¼º¿¡ °üÇÑ ¸¹Àº ¿¬±¸°¡ ÀÖ¾î¿Ô´Ù. ¶ÇÇÑ
50°³ÀÇ ¾Æ¹Ì³ë»êÀ¸·Î ÀÌ·ç¾îÁø transforming growth factor-¥á12(ÀÌÇÏ TGF-
¥á)´Â EGF¿Í ¼ö¿ëü¸¦ °øÀ¯Çϸç, ¼¼Æ÷ÀÇ ¼ºÀå, ÀüÀÌ »Ó ¾Æ´Ï¶ó Ç÷°ü»ý¼º°ú ¼¼Æ÷ÀÇ ÀÌÇü¼ºÈ­
µî¿¡ °ü¿©Çϴµ¥, ¹æ±¤µµ´¢, ¿äµµ°üÀ¯Ä¡, ¹æ±¤°æ½Ã¼ú, °æ¿äµµ¹æ±¤¼ÒÀÛ°ú ÀýÁ¦¼ú µî ¿©·¯ ÇüÅÂ
ÀÇ ¿ä·Î»óÇÇ ¼Õ»ó½Ã¿¡ ¿äÁß ³óµµ°¡ Áõ°¡ÇÏ´Â °ÍÀ¸·Î º¸°íµÇ¾ú´Ù.
°á·Ð
ÀúÀÚµéÀº ÀÎü ÀÌÇà»óÇÇ¾Ï ¼¼Æ÷ÁÖ-T24, KK47, KU-1¿Í EGF, TGF-¥á ¼ºÀåÀÎÀÚ¸¦ ÀÌ¿ë
ÇÑ ½ÇÇè¿¡¼­ ´ÙÀ½°ú °°Àº °á·ÐÀ» ¾ò¾ú´Ù.
1. ¹«Ç÷û ¹èÁö¿¡ EGF¸¦ Åõ¿©ÇÏ¿´À» ¶§ ¼¼ °¡Áö ¼¼Æ÷ÁÖ¿¡¼­ ´ëÁ¶±º¿¡ ºñÇÏ¿© À¯ÀÇÇÑ ¼ºÀå
ÃËÁø È¿°ú¸¦ ¾òÀ» ¼ö ÀÖ¾ú´Ù.
2. ¹«Ç÷û ¹èÁö¿¡ TGF-¥á¸¦ Åõ¿©ÇÏ¿´À» ¶§ ¼¼ °¡Áö ¼¼Æ÷ÁÖ¿¡¼­ ´ëÁ¶±º¿¡ ºñÇÏ¿© À¯ÀÇÇÑ
¼ºÀåÃËÁø È¿°ú¸¦ ¾òÀ» ¼ö ÀÖ¾ú´Ù.
3. ¹«Ç÷û ¹èÁö¿¡ EGF, TGF-¥á¸¦ ÇÔ²² Åõ¿©ÇÏ¿´À» ¶§ ¼¼ °¡Áö ¼¼Æ÷ÁÖ¿¡¼­ ´ëÁ¶±º¿¡ ºñÇÏ
¿© ¶ÇÇÑ °¢°¢ÀÇ ¼ºÀåÀÎÀÚ¸¦ ´Üµ¶ Åõ¿©ÇÏ¿´À» ¶§¿¡ ºñÇÏ¿© À¯ÀÇÇÑ ¼ºÀåÃËÁø È¿°ú¸¦ ¾òÀ» ¼ö
ÀÖ¾ú´Ù.
4. ¼¼ °¡Áö °æ¿ì ¸ðµÎ¿¡¼­ ¼ºÀåÀÎÀÚÀÇ ³óµµÁõ°¡¿¡ µû¸¥ ¼¼Æ÷ ¼ºÀåÃËÁø È¿°úÀÇ À¯ÀÇÇÑ Â÷ÀÌ
´Â °üÂûµÇÁö ¾Ê¾Ò´Ù.
5. ÀÎü ÀÌÇà»óÇÇ¾Ï ¼¼Æ÷ÁÖ¿¡ ´ëÇÑ EGF TGF-¥áÀÇ ¼ºÀåÃËÁø È¿°ú´Â ¼ºÀåÀÎÀÚ¿Í ¼ö¿ëüÀÇ
¾ç »çÀÌÀÇ »ê¼úÀûÀÎ °ü°è »Ó ¾Æ´Ï¶ó ¼ö¿ëü¿¡ ´ëÇÑ Ä£È­µµ,¼¼Æ÷¿¡ ÀÇÇÑ ÀÚ°¡ºÐºñ, ¼¼Æ÷ÀÇ »ý
¹°ÇÐÀû ¹ÝÀÀµµÀÇ º¯È­ ¹× ¼ºÀåÀÎÀÚ¿¡ ÀÇÇÑ ¼ö¿ëüÀÇ ´ë»çº¯È­ µî ¿©·¯ °¡Áö ¿ä¼Ò°¡ °ü·ÃµÇ
¾î ÀÖ´Â º¹ÇÕÀûÀÎ ±âÀüÀ¸·Î »ç·áµÈ´Ù.
#ÃÊ·Ï#
Purpose: We evaluated the effects of epidermal growth factor(EGF) and transforming
growth factors (TGF-¥á) on the growth of human transitional cell carcinoma cell lines.
Materials and Methods: T-24, KK47 and KU-1 cell lines established from human
transitional cell carcinoma tissues were used. We cultured the cell lines in serum-free
media for 48 hours and then administered EGF and TGF-¥á in the concentrations of
0.1ng/ml, 1ng/ml, 10ng/ml and 100ng/m1 respectively. We analysed the effects by MTT
assay at 144 hours.
Results: There were statistically significant stimulatory effects on the growth of three
cell lines in all cultures. Enhanced growth was also observed in the culture with
administration of EGF and TGF-¥á simultaneously. None of stimulatory effects were
dose-related.
Conclusions: We should take into consideration of possible role of EGF which are
excreted in urine in very high concentration in a biologically active form and TGF-¥á of
which urinary level increases with various type of bladder injuries in occurrence,
progression and recurrence of transitional cell carcinoma of urothelium.

Å°¿öµå

Epidermal growth factor; Transforming growth factors; Human transitional cell carcinoma cell lines;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS